Bharat Biotech International Limited (BBIL), a pioneer in affordable indigenous vaccine development and manufacturing, ...
Gene therapy pioneer Jim Wilson and researcher Kiran Musunuru are using contrasting approaches to overcome “irrational ...
A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...
Although cystic fibrosis is a single gene mutation, there are more than 1,000 different ways the CFTR gene can mutate in ...
Scientists at the Allen Institute have made a major breakthrough in research for people living with Dravet Syndrome, which is ...
Vaccine manufacturer Bharat Biotech International Limited (BBIL) is making a foray into the cell and gene therapy (CGT) space ...
To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as Zolgensma, could be approved for a broad range of spinal muscular atrophy ...
Bharat Biotech aims to democratize gene therapies, traditionally considered prohibitively expensive and available primarily ...
An intravenous form of the gene therapy is already approved and sold as Zolgensma in the US for patients less than 2 years of age.
BBIL's 50,000-square-foot CGT facility advances its mission to deliver life-saving treatments for haematological malignancies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback